Drugs / Allogenic human adipose-derived stem cells
Allogenic human adipose-derived stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01440699 | Sep 2011 → Oct 2012 | Crohn disease | Anterogen Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogenic human adipose-derived stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01440699 ↗ |
| Modality | Cell therapy | “adipose-derived stem cells” NCT01440699 ↗ |
| Route | Other | “injected once along the fistula” NCT01440699 ↗ |